Conversion of five proluciferin esters by human cytochrome P450 enzymes.
cytochrome P450
drug metabolism
fission yeast
luminescence
proluciferin ester
Journal
Biotechnology journal
ISSN: 1860-7314
Titre abrégé: Biotechnol J
Pays: Germany
ID NLM: 101265833
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
07
04
2021
received:
06
01
2021
accepted:
09
04
2021
pubmed:
29
4
2021
medline:
10
7
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
Probe substrates are an important tool for activity monitoring of human drug metabolizing enzymes such as cytochromes P450 (CYPs). In the present study we have tested human CYPs for metabolization of five proluciferin ester substrates which had previously only been known to be hydroxylated by CYP26A1. It was found that these substrates were converted by another 21 human CYPs, which belong to the CYP families 1 to 4, 7, and 26. Thus, 66 new pairs of enzyme and substrate were identified. Correlation analysis indicated the presence of three distinct sets of enzymes with high similarity in their activity profiles that encompass a total of 16 individual enzymes. Some of these newly identified correlations may serve as a starting point for further study of those human CYPs whose activities are not yet satisfactorily understood.
Sections du résumé
BACKGROUND
BACKGROUND
Probe substrates are an important tool for activity monitoring of human drug metabolizing enzymes such as cytochromes P450 (CYPs).
BRIEF METHODS
UNASSIGNED
In the present study we have tested human CYPs for metabolization of five proluciferin ester substrates which had previously only been known to be hydroxylated by CYP26A1.
MAJOR RESULTS
RESULTS
It was found that these substrates were converted by another 21 human CYPs, which belong to the CYP families 1 to 4, 7, and 26. Thus, 66 new pairs of enzyme and substrate were identified. Correlation analysis indicated the presence of three distinct sets of enzymes with high similarity in their activity profiles that encompass a total of 16 individual enzymes.
CONCLUSIONS
CONCLUSIONS
Some of these newly identified correlations may serve as a starting point for further study of those human CYPs whose activities are not yet satisfactorily understood.
Identifiants
pubmed: 33909340
doi: 10.1002/biot.202100007
doi:
Substances chimiques
Esters
0
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2100007Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Winkler, M., Geier, M., Hanlon, S. P., Nidetzky, B., & Glieder, A. (2018). Human enzymes for organic synthesis. Angewandte Chemie International Edition England, 57, 13406-13423.
Ortiz De Montellano, P. R. (2015). (Ed.). Cytochrome P450: Structure, Mechanism and Biochemistry. New York: Springer.
Munro, A. W., Mclean, K. J., Grant, J. L., & Makris, T. M. (2018). Structure and function of the cytochrome P450 peroxygenase enzymes. Biochemical Society Transactions, 46, 183-196.
Nelson, D. R. (2018). Cytochrome P450 diversity in the tree of life. Biochimica et Biophysica Acta, 1866, 141-154.
Urlacher, V. B., & Girhard, M. (2019). Cytochrome P450 monooxygenases in biotechnology and synthetic biology. Trends in Biotechnology, 37, 882-897.
Li, S., Du, L., & Bernhardt, R. (2020). Redox partners: Function modulators of bacterial P450 enzymes. Trends in Microbiology, 28, 445-454.
Nebert, D. W., Wikvall, K., & Miller, W. L. (2013). Human cytochromes P450 in health and disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 368, 20120431.
Manikandan, P., & Nagini, S. (2018). Cytochrome P450 structure, function and clinical significance: A review. Current Drug Targets, 19, 38-54.
Hannemann, F., Bichet, A., Ewen, K. M., & Bernhardt, R. (2007). Cytochrome P450 systems-biological variations of electron transport chains. Biochimica et Biophysica Acta, 1770, 330-344.
Guengerich, F. P. (2018). Mechanisms of cytochrome P450-catalyzed oxidations. ACS Catalysis, 8, 10964-10976.
Fanni, D., Pinna, F., Gerosa, C., Paribello, P., Carpiniello, B., Faa, G., & Manchia, M. (2021). Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. Drug Development Research. https://doi.org/10.1002/ddr.21778
Berman, H., Henrick, K., & Nakamura, H. (2013). Announcing the worldwide Protein Data Bank. Nature Structural Biology, 10, 980.
Di, L., & Kerns, E. H. (2016). Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, Academic Press.
Steyn, S. J., & Varma, M. V. S. (2020). Cytochrome-P450-mediated drug-drug interactions of substrate drugs: Assessing clinical risk based on molecular properties and an extended clearance classification system. Molecular Pharmaceutics, 17, 3024-3032.
Yang, X., Hutter, M., Goh, W. W., & Bureik, M. (2017). CYP4Z1 - A human cytochrome P450 enzyme that might hold the key to curing breast cancer. Current Pharmaceutical Design, 23, 2060-2064.
Licznerska, B., & Baer-Dubowska, W. (2020). What might the presence of 'orphan' CYP450 isoforms in breast epithelial cells mean for the future of targeted therapeutics? Expert Opinion on Drug Metabolism and Toxicology, 17, 1-3.
Cali, J. J., Ma, D., Sobol, M., Simpson, D. J., Frackman, S., Good, T. D., Daily, W. J., & Liu, D. (2006). Luminogenic cytochrome P450 assays. Expert Opinion on Drug Metabolism and Toxicology, 2, 629-645.
Gomi, K., & Kajiyama, N. (2001). Oxyluciferin, a luminescence product of firefly luciferase, is enzymatically regenerated into luciferin. Journal of Biological Chemistry, 276, 36508-36513.
Giga-Hama, Y. (1997). In: Giga-Hama, Y., Kumagai, H. (Eds.), Fission Yeast Schizosaccharomyces pombe: An Attractive Host for Heterologous Protein Production Foreign Gene Expression in Fission Yeast Schizosaccharomyces pombe. Berlin, Germany: Springer-Verlag, 3-28.
Bureik, M., Schiffler, B., Hiraoka, Y., Vogel, F., & Bernhardt, R. (2002). Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry, 41, 2311-2321.
Dragan, C. A., Hartmann, R. W., & Bureik, M. (2006). A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. The Journal of Enzyme Inhibition and Medicinal Chemistry, 21, 547-556.
Peters, F. T., Dragan, C. A., Wilde, D. R., Meyer, M. R., Zapp, J., Bureik, M., & Maurer, H. H. (2007). Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone. Biochemical Pharmacology, 74, 511-520.
Peters, F. T., Dragan, C. A., Kauffels, A., Schwaninger, A. E., Zapp, J., Bureik, M., & Maurer, H. H. (2019). Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6-a versatile alternative to multistep chemical synthesis. Journal of Analytical Toxicology, 33, 190-197.
Peters, F. T., Dragan, C. A., Schwaninger, A. E., Sauer, C., Zapp, J., Bureik, M., & Maurer, H. H. (2009). Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine. Forensic Science International, 184, 69-73.
Zöllner, A., Dragan, C. A., Pistorius, D., Muller, R., Bode, H. B., Peters, F. T., Maurer, H. H., & Bureik, M. (2009). Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biological Chemistry, 390, 313-317.
Tin, M. K., Hakki, T., & Bernhardt, R. (2011). Fission yeast Schizosaccharomyces pombe as a new system for the investigation of corticosterone methyloxidase deficiency-causing mutations. The Journal of Steroid Biochemistry and Molecular Biology, 124, 31-37.
Parr, M. K., Zöllner, A., Fussholler, G., Opfermann, G., Schlorer, N., Zorio, M., Bureik, M., & Schanzer, W. (2012). Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - Insights from metandienone metabolism. Toxicology Letters, 213, 381-391.
Yan, Q., Machalz, D., Zollner, A., Sorensen, E. J., Wolber, G., & Bureik, M. (2017). Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast. Biochemical Pharmacology, 146, 174-187.
Durairaj, P., Fan, L., Du, W., Ahmad, S., Mebrahtu, D., Sharma, S., Ashraf, R. A., Liu, J., Liu, Q., & Bureik, M. (2019). Functional expression and activity screening of all human cytochrome P450 enzymes in fission yeast. FEBS Letters, 593, 1372-1380.
Stoll, A., Loke, S., Joseph, J. F., Machalz, D., De La Torre, X., Botre, F., Wolber, G., Bureik, M., & Parr, M. K. (2019). Fine-mapping of the substrate specificity of human steroid 21-hydroxylase (CYP21A2). The Journal of Steroid Biochemistry and Molecular Biology, 194, 105446.
Fan, L. B., Joseph, J. F., Durairaj, P., & Parr, M. K. (2019). Bureik, M., Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1. Biological Chemistry, 400, 625-628.
Durairaj, P., Fan, L., Machalz, D., Wolber, G., & Bureik, M. (2019). Functional characterization and mechanistic modeling of the human cytochrome P450 enzyme CYP4A22. FEBS Letters, 593, 2214-2225.
Krauser, S., Weyler, C., Blass, L. K., & Heinzle, E. (2013). Directed multistep biocatalysis using tailored permeabilized cells. Advances in Biochemical Engineering/Biotechnology, 137, 185-234.
Cali, J. J., Ma, D., Wood, M. G., Meisenheimer, P. L., & Klaubert, D. H. (2012). Bioluminescent assays for ADME evaluation: Dialing in CYP selectivity with luminogenic substrates. Expert Opinion on Drug Metabolism and Toxicology, 8, 1115-1130.
Sharma, S., Liu, J., Zhang, X., Sharma, S. S., Sorensen, E. J., & Bureik, M. (2020). New luciferin-based probe substrates for human CYP26A1. Biochemistry and Biophysics Reports, 24, 100861.
Sharma, S. S., Sharma, S., & Bureik, M. (2020). Screening of the whole human cytochrome P450 complement (CYPome) with enzyme bag cocktails. Journal of Pharmaceutical Analysis, 10, 271-276.
Sharma, S., Durairaj, P., & Bureik, M. (2020). Rapid and convenient biotransformation procedure for human drug metabolizing enzymes using permeabilized fission yeast cells. Analytical Biochemistry, 607, 113704.
Alfa, C., Fantes, P., Hyams, J., Mcleod, M., & Warbrick, E. (1993). Experiments With Fission Yeast. A Laboratory Course Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press.
Liu, J., Machalz, D., Wolber, G., Sorensen, E. J., & Bureik, M. (2020). New proluciferin substrates for human CYP4 family enzymes. Applied Biochemistry and Biotechnology, 193(1), 218-237.
Cali, J. J., Klaubert, D., Daily, W., Ho, S. K. S., Frackman, S., Hawkins, E., & Wood, K. V. (2017).
Lipinski, C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced Drug Delivery Reviews, 101, 34-41.
Langford, E., Schwertman, N., & Owens, M. (2001). Is the property of being positively correlated transitive? The American Statistician, 55, 322-325.
Mcdonald, M. G., Ray, S., Amorosi, C. J., Sitko, K. A., Kowalski, J. P., Paco, L., Nath, A., Gallis, B., Totah, R. A., Dunham, M. J., Fowler, D. M., & Rettie, A. E. (2017). Expression and functional characterization of breast cancer-associated cytochrome P450 4Z1 in saccharomyces cerevisiae. Drug Metabolism and Disposition, 45, 1364-1371.
Machalz, D., Li, H., Du, W., Sharma, S., Liu, S., Bureik, M., & Wolber, G. (2021). Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor. European Journal of Medicinal Chemistry, 215, 113255.
Du, W., Machalz, D., Yan, Q., Sorensen, E. J., Wolber, G., & Bureik, M. (2020). Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1. Biochemical Pharmacology, 174, 113850.